Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.67 |
| ▸ | MET | P08581 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL4717370 | 0.98 | GPR84 (0.65) | GPR84METKMT2ACYP2D6KDM4E | |
| Iodomethane SCHEMBL9399868 | 0.97 | GPR84 (0.63) | GPR84METKMT2ACYP2D6KDM4E | |
| Ethoxycarbonyl Group SCHEMBL28008457 | 0.85 | GPR84 (0.50) | GPR84METKMT2ACYP2D6KDM4E | |
| SCHEMBL30886870 | 0.84 | GPR84 (0.63) | GPR84METMTNR1ASLC6A4FGFR1 | |
| SCHEMBL6359455 | 0.84 | GPR84 (0.63) | GPR84METMTNR1ASLC6A4FGFR1 | |
| Hydrochloric Acid SCHEMBL4869205 | 0.83 | GPR84 (0.61) | GPR84METMTNR1ASLC6A4FGFR1 | |
| SCHEMBL31385845 | 0.81 | GPR84 (0.73) | GPR84METKMT2AMTNR1AFGFR1 | |
| SCHEMBL2692513 | 0.81 | GPR84 (0.73) | GPR84METKMT2AMTNR1AFGFR1 | |
| SCHEMBL27911675 | 0.80 | GPR84 (1.00) | GPR84METKMT2ACYP2D6MEN1 | |
| SCHEMBL2217980 | 0.79 | GPR84 (0.76) | GPR84METKMT2ACYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376464-A1 | Compounds for treatment a coronavirus infection | TRAWSFYNYDD THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4540227-A2 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | Trawsfynydd Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119630642-A | Compounds for the treatment of coronavirus infections | 特劳斯芬尼德治疗股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2023245162-A2 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023245162-A2 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-3177621-B1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | UNIV REGENSBURG (DE) | 2021-11-10 | — | — | EP | disclosed |
| EP-3177621-B1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | UNIV REGENSBURG (DE) | 2021-11-10 | — | — | EP | disclosed |
| CN-106999536-B | Macrocyclic inhibitors of PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | 百时美施贵宝公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| EP-0724572-A1 | FUSED TRICYCLIC HETEROAROMATIC DERIVATIVES AS DOPAMINE RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 1996-08-07 | — | — | EP | disclosed |
| WO-1996005200-A1 | TETRAHYDROPYRIDINYLMETHYL DERIVATIVES OF PYRROLO[2,3-b]PYRIDINE | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
| EP-0687267-A1 | PYRROLO-PYRIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1995-12-20 | — | — | EP | disclosed |
| US-5432177-A | Pyrrolo-pyridine derivatives | MERCK SHARPE & DOHME LTD. (GB) | 1995-07-11 | — | — | US | disclosed |
| WO-1995014690-A1 | MORPHOLINE DERIVATIVES AS DOPAMINE RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1995-06-01 | — | — | WO | disclosed |
| WO-1995014672-A1 | ISOXAZOLE AND PYRAZOLE DERIVATIVES AS DOPAMINE RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1995-06-01 | — | — | WO | disclosed |
| WO-1995007893-A1 | FUSED TRICYCLIC HETEROAROMATIC DERIVATIVES AS DOPAMINE RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1995-03-23 | — | — | WO | disclosed |
| EP-0623618-A2 | Pyrrolo-pyridine derivatives | MERCK SHARP & DOHME LTD. (GB) | 1994-11-09 | — | — | EP | disclosed |
| WO-1994020497-A1 | PYRROLO-PYRIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
| WO-1994020459-A2 | PYRROLO-PYRIDINE DERIVATIVES AS DOPAMINE RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376464-A1 | Compounds for treatment a coronavirus infection | ACE2, ACE, TMPRSS2 | GPR84 1389/4885MET 1372/4885KMT2A 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.